QLGN vs. CSCI, DWTX, BLRX, ATHA, PHXM, TLPH, APRE, NERV, CYCN, and LSB
Should you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include COSCIENS Biopharma (CSCI), Dogwood Therapeutics (DWTX), BioLineRx (BLRX), Athira Pharma (ATHA), PHAXIAM Therapeutics (PHXM), Talphera (TLPH), Aprea Therapeutics (APRE), Minerva Neurosciences (NERV), Cyclerion Therapeutics (CYCN), and Lakeshore Biopharma (LSB). These companies are all part of the "pharmaceutical products" industry.
Qualigen Therapeutics vs.
COSCIENS Biopharma (NASDAQ:CSCI) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking.
In the previous week, Qualigen Therapeutics had 2 more articles in the media than COSCIENS Biopharma. MarketBeat recorded 6 mentions for Qualigen Therapeutics and 4 mentions for COSCIENS Biopharma. Qualigen Therapeutics' average media sentiment score of 0.31 beat COSCIENS Biopharma's score of 0.29 indicating that Qualigen Therapeutics is being referred to more favorably in the news media.
Qualigen Therapeutics has a net margin of 0.00% compared to COSCIENS Biopharma's net margin of -428.43%. Qualigen Therapeutics' return on equity of 0.00% beat COSCIENS Biopharma's return on equity.
Qualigen Therapeutics has lower revenue, but higher earnings than COSCIENS Biopharma.
COSCIENS Biopharma has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500.
0.7% of COSCIENS Biopharma shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 0.1% of COSCIENS Biopharma shares are owned by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Qualigen Therapeutics received 7 more outperform votes than COSCIENS Biopharma when rated by MarketBeat users.
Summary
Qualigen Therapeutics beats COSCIENS Biopharma on 8 of the 12 factors compared between the two stocks.
Get Qualigen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Qualigen Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:QLGN) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy QLGN Stock Free QLGN Stock Alerts